Risk of Cardiovascular Events with Cyclin-Dependent Kinases 4 and 6 (CDK 4/6) Inhibitors among Patients with Advanced Breast Cancer: A Systematic Review and Network Meta-Analysis. [PDF]
Rev Cardiovasc Med, 2023 Liu YS, Dong K, Park C.
europepmc +1 more source
RTA‐408 Enhances Radiosensitivity and Inhibited Tumor Progression via JNK Pathway in Glioblastoma
The Kaohsiung Journal of Medical Sciences, EarlyView.ABSTRACT Glioblastoma (GBM) is an aggressive brain tumor with poor prognosis owing to its high invasiveness and resistance to therapy. RTA‐408, a synthetic triterpenoid and nuclear factor erythroid 2‐related factor 2 activator, exhibits anti‐inflammatory and anti‐cancer properties; however, its effects on GBM remain unclear. This study investigated the
Hung‐Pei Tsai +6 more
wiley +1 more source
Efficacy of cyclin-dependent kinases 4 and 6 inhibitors in the treatment of HR +/HER2 - advanced breast cancer: a meta-analysis. [PDF]
Eur J Med ResDanbala IA +7 more
europepmc +1 more source
Cyclin-Dependent Kinases (CDK) and Their Role in Diseases Development-Review. [PDF]
Int J Mol Sci, 2021 Łukasik P, Załuski M, Gutowska I.
europepmc +1 more source
The Kaohsiung Journal of Medical Sciences, EarlyView.ABSTRACT Since 2019, coronavirus disease 2019 (COVID‐19) has been associated with increased risks of preterm birth and placental complications. We prospectively investigated alterations in microRNAs (miRNAs) and cytokines in placental and amniotic tissues from pregnant women with and without COVID‐19 to evaluate the infection's impact on pregnancy ...
Wei‐Chun Chen +3 more
wiley +1 more source
Biomarkers of primary and secondary resistance to cyclin dependent kinases 4 and 6 inhibitors in metastatic estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast cancer: a narrative review. [PDF]
Transl Breast Cancer ResStravodimou A, Voutsadakis IA.
europepmc +1 more source
Multimodal perturbation analyses of cyclin-dependent kinases reveal a network of synthetic lethalities associated with cell-cycle regulation and transcriptional regulation. [PDF]
Sci Rep, 2023 Ford K +18 more
europepmc +1 more source
Movement Disorders, EarlyView.Abstract Background Leucine‐rich repeat kinase 2 (LRRK2) kinase inhibition is a promising therapeutic strategy for Parkinson's disease (PD), but the functional impact of Asian‐prevalent LRRK2 p.G2385R and p.R1628P variants remains unclear. Robust patient stratification and target engagement markers are needed for global LRRK2‐targeted trials ...
Tzi Shin Toh +17 more
wiley +1 more source